Anlotinib

Generic Name: Anlotinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₂FN_₃O_₃

CAS Number: 1058156-90-3

Unique Ingredient Identifier: GKF8S4C432

Background: Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Indication: 用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。

用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Not Applicable

Recruiting

Conditions: Desmoid

Interventions: Drug: Anlotinib

First Posted Date: 2022-08-08

Last Posted Date: 2023-10-30

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT05490667

Locations: 🇨🇳
Department of Bone and Soft Tissue ,Henan Cancer Hospital, Zhengzhou, Henan, China

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Efficacy and Safety
Locally Advanced Non-small Cell Lung Cancer

Interventions: Drug: Chemotherapy
Drug: Anlotinib
Radiation: Radiotherapy
Drug: Immunotherapy

First Posted Date: 2022-08-01

Last Posted Date: 2022-11-21

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT05481775

Locations: 🇨🇳
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

Phase 2

Not yet recruiting

Conditions: Stage IV Esophagus Squamous Cell Carcinoma

Interventions: Drug: Camrelizumab
Drug: Anlotinib
Drug: Irinotecan
Drug: Paclitaxel
Drug: Paclitaxel-albumin
Drug: Docetaxel

First Posted Date: 2022-04-11

Last Posted Date: 2022-04-11

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 80

Registration Number: NCT05322499

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Sintilimab
Drug: Anlotinib

First Posted Date: 2022-04-01

Last Posted Date: 2022-04-01

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 93

Registration Number: NCT05306847

Anlotinib Retrospective Study for Esophageal Cancer

Completed

Conditions: Esophageal Neoplasms

Interventions: Drug: Anlotinib

First Posted Date: 2022-03-31

Last Posted Date: 2022-03-31

Lead Sponsor: Feng Wang

Target Recruit Count: 300

Registration Number: NCT05303740

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Anlotinib
Drug: Irinotecan
Drug: Penpulimab

First Posted Date: 2022-02-08

Last Posted Date: 2024-07-03

Lead Sponsor: Fudan University

Target Recruit Count: 44

Registration Number: NCT05229003

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Not Applicable

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Anlotinib

First Posted Date: 2022-02-01

Last Posted Date: 2022-02-01

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 30

Registration Number: NCT05218759

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Eribulin Mesylate
Drug: Anlotinib

First Posted Date: 2022-01-25

Last Posted Date: 2022-11-23

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 80

Registration Number: NCT05206656

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial

Phase 2

Conditions: Advanced or Metastatic Paraganglioma/ Pheochromocytoma

Interventions: Drug: Anlotinib

First Posted Date: 2021-11-24

Last Posted Date: 2021-11-24

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 20

Registration Number: NCT05133349

Locations: 🇨🇳
The First Affiliated Hospital of Nanjing Medical Univerity, Nanjing, Jiangsu, China

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.

Phase 2

Completed

Conditions: Platinum-resistant Recurrent Clear Cell Ovarian Cancer

Interventions: Drug: Niraparib
Drug: Anlotinib

First Posted Date: 2021-11-23

Last Posted Date: 2023-01-31

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 6

Registration Number: NCT05130515

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy